



PerkinElmer Partners with Cerep for Custom Drug Discovery Solutions

WALTHAM, Mass., Apr 06, 2008 (BUSINESS WIRE) --PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, and Cerep SA (Eurolist: Cerep), a leading provider of drug candidate screening and profiling technologies, today announced the signing of a supply and co-marketing agreement to deliver custom drug discovery services. Under the terms of the agreement, PerkinElmer will exclusively market Cerep's target screening and profiling services to its customers, and the companies will jointly promote PerkinElmer's assay technologies and Cerep services to the drug discovery market.

"This agreement represents the latest step in our strategy to build the most comprehensive offering in biochemical and cellular screening for drug discovery," said Robert F. Friel, president and chief executive officer, PerkinElmer, Inc. "Our customers will benefit from direct access to Cerep's expertise in high throughput screening and profiling services, while PerkinElmer will be able to extend the reach of our leading assay technologies and assay development services into key drug discovery markets."

"Cerep is committed to providing the highest quality services in drug discovery and drug development and we are pleased to work with an established leader of drug discovery technologies to further strengthen our offerings," said Thierry Jean, chairman and chief executive officer, Cerep. "This agreement with PerkinElmer enables us to support our customers' complete drug discovery needs, from assay design to target screening and profiling, by adding a range of enabling assay technologies to our drug screening and profiling services."

This agreement provides PerkinElmer customers with an option to work with a single vendor throughout the entire drug discovery process. Cerep customers will now have access to several key assay development and detection platforms from PerkinElmer's Bio-discovery business, including AlphaScreen[®], AlphaLISA[™], LANCE[®], and LANCE[®] Ultra[™] for G protein-coupled receptor (GPCR) and kinase assay development.

GPCRs and protein kinases represent a wide range of therapeutic targets in areas including cancer, central nervous system disorders, cardiac dysfunction and diabetes, making them among the most important areas of study in today's pharmaceutical and biotech laboratories.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Cerep's mission is to provide pharmaceutical companies with high quality services in drug discovery and drug development. Cerep provides, both in Europe and in the United States, solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development.

Additional information is available through www.cerep.com

Investor Relations:

PerkinElmer, Inc.

Michael A. Lawless

781-663-5659

or

Media Contact:

PerkinElmer, Inc.

Stephanie Wasco

781-663-5701

or

Cerep

Thierry Jean

Chairman & CEO

Michele Arnoe

Global Head

Business Development

Tel. +33 (0)1 45 64 44 60

fincom@cerep.fr

SOURCE: PerkinElmer, Inc.